13 completed, 2 terminated, 2 unknown, 1 active not recruiting. 5 Phase 3, 4 Phase 1, 3 Phase 2, 3 Phase 4, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 5 |
| Phase 1 | 4 | Completed 3, Terminated 1 |
| Phase 2 | 3 | Completed 3 |
| Phase 4 | 3 | Active not recruiting 1, Completed 1, Unknown 1 |
| Not applicable | 1 | Unknown 1 |
Follow Peyronie's Disease: new trials by email Literature Review of Peyronie's Disease trials Research Report on Peyronie's Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Real-World Data Study to Understand Effectiveness of Treatments in Peyronie's Disease Peyronie's Disease | Terminated | Endo USA Inc., a Keenova Therapeutics Company | 29 | 2023-06-20 | 2024-04-16 | |
| Intralesional Hyaluronic Acid and Verapamil Injection in Peyronie's Disease Intralesional treatment with Hyaluronic acid, Intralesional treatment with Verapamil - Peyronie's Disease, Hyaluronic Acid | Not applicable | Unknown | Benha University | 42 | 2023-05-20 | 2023-05-11 |
| Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders CCH administration, Control - Crossover to CCH, RestoreX - Peyronie's Disease | Phase 4 | Completed | Charitable Union for the Research and Education of Peyronie's Disease | 40 | 2021-09-20 | 2026-08-26 |
| Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis AlloRx - Erectile Dysfunction, Peyronie's Disease | Phase 1 | Terminated | The Foundation for Orthopaedics and Regenerative Medicine | 20 | 2021-09-12 | 2026-10-20 |
| Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex] (CCH), Penile Plication Surgery, Incision and Grafting (I&G) Surgery - Peyronie's Disease | Phase 4 | Active not recruiting | Charitable Union for the Research and Education of Peyronie's Disease | 40 | 2020-12-30 | 2026-08-26 |
| Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response Xiaflex® 0.58 mg - Peyronie's Disease | Phase 4 | Unknown | Manhattan Medical Research Practice, PLLC | 20 | 2018-10-04 | 2018-12-07 |
| Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease Subjects Previously Treated with AA4500 - Peyronie's Disease | Completed | Endo USA Inc., a Keenova Therapeutics Company | 184 | 2014-11-01 | 2018-06-20 | |
| An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease AA4500, ErecAid® Esteem® Manual Vacuum Therapy System, Investigator Modeling - Peyronie's Disease | Phase 3 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 30 | 2014-10-01 | 2017-11-08 |
| Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs) - Peyronie's Disease | Phase 1 | Completed | Melissa Marchand | 5 | 2013-08-01 | 2015-03-20 |
| Peyronie's Disease Treatment Protocol H-100, Placebo - Peyronie's Disease | Phase 1 | Completed | Hybrid Medical | 22 | 2013-06-01 | 2014-02-26 |
| Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease Vitamin D2, Vitamin E, Testosterone Pellets - Peyronie's Disease | Phase 1 | Completed | Men's Health Boston | 75 | 2013-05-23 | 2018-03-29 |
| A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease AA4500 - Peyronie's Disease | Phase 3 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 189 | 2012-09-01 | 2017-10-05 |
| Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease AA4500 - Peyronie's Disease | Phase 2 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 20 | 2011-09-01 | 2017-10-05 |
| A Study of AA4500 in Men With Peyronie's Disease AA4500 - Peyronie's Disease | Phase 3 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 348 | 2010-11-01 | 2017-10-05 |
| Study of AA4500 in the Treatment of Peyronie's Disease AA4500, Placebo - Peyronie's Disease | Phase 3 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 418 | 2010-10-01 | 2017-10-05 |
| Study of AA4500 in the Treatment of Peyronie's Disease AA4500, Placebo - Peyronie's Disease | Phase 3 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 418 | 2010-09-01 | 2017-10-05 |
| H-22411: BOTOX® for Peyronie's Disease 100 units of Botulinum Toxin Type A, Preservative free normal saline, 100 units Botulinum Toxin A - Peyronie's Disease | Phase 2 | Completed | Mohit Khera | 12 | 2009-08-07 | 2024-04-08 |
| The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease AA4500, Placebo - Peyronie's Disease | Phase 2 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 147 | 2008-08-01 | 2017-10-05 |
Penile Induration (18) · Airway Obstruction (1) · Cystitis, Interstitial (1) · Erectile Dysfunction (1) · Recurrence (1) · Surgical Wound (1)
Connective Tissue Diseases (18) · Genital Diseases (18) · Genital Diseases, Male (18) · Male Urogenital Diseases (18) · Penile Diseases (18) · Skin and Connective Tissue Diseases (18) · Urogenital Diseases (18) · Cystitis (1) · Disease Attributes (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Mental Disorders (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Respiration Disorders (1)
Microbial Collagenase (9) · xiapex (3) · Botulinum Toxins, Type A (1) · Crossing Over, Genetic (1) · Ergocalciferols (1) · Hyaluronic Acid (1) · Injections (1) · Surgical Procedures, Operative (1) · Testosterone (1) · Transplantation (1) · Verapamil (1) · Vitamin E (1) · complement H100 (1)
Endo USA Inc., a Keenova Therapeutics Company (9) · Charitable Union for the Research and Education of Peyronie's Disease (2) · Benha University (1) · Hybrid Medical (1) · Manhattan Medical Research Practice, PLLC (1) · Melissa Marchand (1) · Men's Health Boston (1) · Mohit Khera (1) · The Foundation for Orthopaedics and Regenerative Medicine (1)
United States (14) · Australia (2) · United Kingdom (2) · Antigua and Barbuda (1) · Denmark (1) · France (1) · Germany (1) · Italy (1) · New Zealand (1) · Spain (1) · Sweden (1)
Gregory J. Kaufman, MD (3) · Gregory Kaufman, MD (2) · Abraham Morgentaler, MD (1) · Chadwick Prodromos, MD (1) · Jed Kaminetsky, MD (1) · Jeffry Twidwell, MD (1) · Landon Trost, MD (1) · Michael P. Zahalsky, M.D. (1) · Mohit Khera, MD, MBA (1) · Neil Shusterman, MD (1) · Veronica Urdaneta, MD (1)